Lv6
2340 积分 2025-01-06 加入
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
4天前
已完结
The outcome of IgAN: a time of reflection in the perspective of new opportunities
12天前
已完结
Iptacopan in IgA Nephropathy — Final 24-Month Data
13天前
已完结
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
16天前
已完结
Current Roles of Neoadjuvant and Perioperative Immunotherapy in Non–Small Cell Lung Cancer
18天前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
25天前
已完结
Nefecon in IgA nephropathy: real-world renal efficacy, safety profile, and treatment response from a 9-month retrospective cohort analysis
1个月前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
1个月前
已完结
Etiopathogenesis of medication-related osteonecrosis of the jaws: a review
1个月前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
1个月前
已完结
皖公网安备34019202002308
